Background No effective therapeutic options for patients with unresectable imatinib-resistant
gastrointestinal stromal tumour are available. We did a randomised, double-blind, placebo-…

Background Gastrointestinal stromal tumour is the most common sarcoma of the intestinal
tract. Imatinib mesylate is a small molecule that inhibits activation of the KIT and platelet-…

PURPOSE It remains a challenge to predict which women with axillary node-negative (ANN)
breast cancer at greatest risk of relapse may benefit most from adjuvant therapy. Increases …

Purpose The ACOSOG (American College of Surgeons Oncology Group) Z9001 (Alliance)
study, a randomized, placebo-controlled trial, demonstrated that 1 year of adjuvant imatinib …

… Telephone 416-586-5371, fax 416-586-5165, e-mail martin.blackstein@utoronto.ca …
Blackstein et al (17) have recently reported that the 5% of GISTs that are KIT-negative may …

For patients with soft tissue sarcoma in an extremity, the outcome is thought to be poor if
lymph node metastasis develops. The purpose of this study was to examine the impact of …

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the
gastrointestinal tract and present predominantly in middle‐aged and older individuals. …

Background Giant cell tumour of the bone (GCTB) is an aggressive osteolytic primary tumour.
GCTB is rich in osteoclast-like giant cells and contains mononuclear cells that express …

Background. This study relates our experience in the diagnosis and treatment of a rare clinical
entity, non‐Hodgkin's primary lymphoma of bone. Methods. Seventeen cases of patients …

Purpose Increases in neu/erbB-2 have been implicated in breast cancer prognosis, but do
not predict all recurrences. On the basis of evidence that p53 mutation is involved in the …